ArticleStem cell research & therapy2025
BRD-K20733377 inhibits ferroptosis and alleviates intervertebral disc degeneration via the STAT3/NFKB1 axis: a multiapproach study.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- UCHL3 drives ferroptosis in nucleus pulposus cells by deubiquitinating HMGB1 to activate NCOA4-mediated ferritinophagy.Autophagy · 2026Article
- Molecular Mechanism Underlying IBRV-Induced Ferroptosis in MDBK Cells via the NFKB1-SLC39A8 Axis.Animals : an open access journal from MDPI · 2026Article
- Beyond the hype: the glycolysis-pyroptosis axis in intervertebral disc degeneration and the path to therapeutic translation.Apoptosis : an international journal on programmed cell death · 2026Article
- Multi-layered integrated shielding: engineering ferroptosis-resistant mesenchymal stem cells for precision therapy of intervertebral disc degeneration.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionIntervertebral disc degeneration (IVDD) is one of the main causes of low back pain. Existing literature has confirmed the occurrence of ferroptosis in IVDD. With the widespread application of artificial intelligence (AI), an increasing number of compounds have been screened for their potential to alleviate IVDD. BRD-K20733377 is one such compound with anti-aging properties. Preliminary experiments have shown that BRD-K20733377 can significantly inhibit cellular ferroptosis. However, research on the potential therapeutic targets and mechanisms of BRD-K20733377 in IVDD remains limited.
objectiveThis study aims to explore the main targets and potential mechanisms of BRD-K20733377 in the treatment of IVDD.
methodsNetwork pharmacology, bioinformatics, machine learning algorithms, molecular docking, molecular dynamics, and Mendelian randomization were used to comprehensively analyze the effects, potential targets, and mechanisms of BRD-K20733377 in IVDD. Rat nucleus pulposus-derived mesenchymal stem cells (NPMSCs) were selected for in vitro experiments. Cell viability was measured by CCK-8 and flow cytometry, while antioxidant defense, lipid peroxidation, and iron metabolism were explored using JC-1, Reactive Oxygen Species (ROS), FerroOrange dye, Lipid peroxides, Malondialdehyde (MDA), and Mitochondrial transmission electron microscopy. The expression levels of ferroptosis-related proteins were detected by Western blot and immunofluorescence. In the rat IVDD model, the effects of BRD-K20733377 on pain threshold, pain behavior, and its therapeutic efficacy were evaluated.
resultsPredictive results identified 30 genes related to ferroptosis in BRD-K20733377 and IVDD, revealing that the potential mechanism of BRD-K20733377 in treating IVDD is closely associated with ferroptosis. In addition, functional enrichment analysis indicated that these genes are involved in multiple signaling pathways. Machine learning algorithms further identified the core targets STAT3 and NFKB1, and Mendelian randomization validated their direct causal relationship with IVDD. In vitro experiments confirmed that BRD-K20733377 inhibited IVDD by reducing intracellular Fe²⁺ levels and lipid peroxidation, thus regulating ferroptosis. Theoretically, BRD-K20733377 may inhibit NPMSCs ferroptosis via STAT3/NFKB1 axis. Ferroptosis-related proteins and immunofluorescence results further supported this mechanism. In vivo experiments showed that BRD-K20733377 significantly improved the behavior of SD rats, reduced pain scores, and alleviated IVDD.
conclusionBRD-K20733377 inhibits ferroptosis through the STAT3/NFKB1 axis, thereby alleviating IVDD. This provides a new perspective for the study of IVDD and could serve as a potential therapeutictarget for IVDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.